NZ790559A - Macrocyclic broad spectrum antibiotics - Google Patents

Macrocyclic broad spectrum antibiotics

Info

Publication number
NZ790559A
NZ790559A NZ790559A NZ79055920A NZ790559A NZ 790559 A NZ790559 A NZ 790559A NZ 790559 A NZ790559 A NZ 790559A NZ 79055920 A NZ79055920 A NZ 79055920A NZ 790559 A NZ790559 A NZ 790559A
Authority
NZ
New Zealand
Prior art keywords
compound
acceptable salt
pharmaceutically acceptable
alkyl
stereoisomer
Prior art date
Application number
NZ790559A
Other versions
NZ790559B2 (en
Inventor
Claudio Sturino
Michael Friedrich Thomas Koehler
Peter Andrew Smith
Dana Winter
Boubacar Sow
Guillaume Pelletier
Jonathan Boudreault
Roy Stéphanie
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NZ790559A publication Critical patent/NZ790559A/en
Publication of NZ790559B2 publication Critical patent/NZ790559B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparing Plates And Mask In Photomechanical Process (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidases SpsB and/or LepB, an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Claims (74)

1. A compound of Formula (I), or a ceutically acceptable salt or stereoisomer f: Formula (I); wherein: R1 is H or -(C1-C6)alkyl optionally substituted with one, two, or three R1a; each R1a is independently halogen, -CN, -ORa, -SRa, -NRcRd, -NO2, -C(=O)Rb, -NRaC(=O)Rb, - C(=O)ORa, -C(=O)NRcRd, -NRaC(=O)NRcRd, -S(=O)2Rb, -S(=O)Rb, -S(=O)2NRcRd, - S(=O)NRcRd, -NRaS(=O)2Rb, -NRaS(=O)2NRcRd, -NRaORa, -NRaC(=O)NRaORa, -O(C1- C6)alkylene-NRcRd, -NRaC(=NRc)Ra, -C(=NRa)NRcRd, -NRaC(=NRa)NRcRd, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two R1a on the same carbon are taken together to form an R2 is H, -NRcRd, or -(C1-C6)alkyl optionally substituted with one, two, or three R2a; each R2a is independently halogen, -CN, -ORa, -SRa, -NRcRd, -NO2, -C(=O)Rb, -NRaC(=O)Rb, - Ra, -C(=O)NRcRd, -NRaC(=O)NRcRd, -S(=O)2Rb, -S(=O)Rb, -S(=O)2NRcRd, - S(=O)NRcRd, -NRaS(=O)2Rb, =O)2NRcRd, -NRaORa, -NRaC(=O)NRaORa, -O(C1- C6)alkylene-NRcRd, -NRaC(=NRc)Ra, -C(=NRa)NRcRd, -NRaC(=NRa)NRcRd, cycloalkyl, heterocycloalkyl, aryl, or aryl; or two R2a on the same carbon are taken together to form an R3 is H, -(C3-C6)cycloalkyl, or -(C1-C6)alkyl optionally tuted with one, two, or three R3a; each R3a is independently halogen, -CN, -ORa, -SRa, -NRcRd, -NO2, Rb, -NRaC(=O)Rb, - C(=O)ORa, -C(=O)NRcRd, -NRaC(=O)NRcRd, -S(=O)2Rb, -S(=O)Rb, -S(=O)2NRcRd, - S(=O)NRcRd, -NRaS(=O)2Rb, -NRaS(=O)2NRcRd, -NRaORa, -NRaC(=O)NRaORa, -O(C1- C6)alkylene-NRcRd, -NRaC(=NRc)Ra, -C(=NRa)NRcRd, -NRaC(=NRa)NRcRd, lkyl, heterocycloalkyl, aryl, or heteroaryl; or two R3a on the same carbon are taken together to form an R4 is H or -(C1-C6)alkyl; 21305059_1 (GHMatters) P117933.NZ.1 X is (C1-C6)alkylene, (C2-C6)alkenylene, (C2-C6)alkynylene, )cycloalkylene, (C2- C7)heterocycloalkylene, arylene, or heteroarylene; wherein the alkylene, alkenylene, alkynylene, cycloalkylene, heterocycloalkylene, arylene, and heteroarylene is optionally substituted with one, two, or three RX; each RX is independently halogen, -CN, -ORa, -NRcRd, -NO2, -C(=O)Rb, -C(=O)ORa, -C(=O)NRcRd, - (C 1-C6)alkyl, -(C1-C6)haloalkyl, -(C1-C6)heteroalkyl, -(C1-C6)hydroxyalkyl, -(C1-C6)aminoalkyl, - (C X on the same carbon are taken together to 3-C7)cycloalkyl, or -(C2-C7)heterocycloalkyl; or two R form an oxo; Y is bond, -O-, -S-, (C1-C6)alkylene, (C2-C6)alkenylene, (C2-C6)alkynylene, (C3-C7)cycloalkylene, (C2- C7)heterocycloalkylene, arylene, or arylene; wherein the alkylene, alkenylene, alkynylene, cycloalkylene, heterocycloalkylene, arylene, and heteroarylene is optionally substituted with one, two, or three RY; each RY is independently halogen, -CN, -ORa, , -NO2, -C(=O)Rb, ORa, -C(=O)NRcRd, - (C 1-C6)alkyl, -(C1-C6)haloalkyl, -(C1-C6)heteroalkyl, -(C1-C6)hydroxyalkyl, -(C1-C6)aminoalkyl, - (C Y on the same carbon are taken together to 3-C7)cycloalkyl, or -(C2-C7)heterocycloalkyl; or two R form an oxo; Z is H, halogen, -CN, -OR10 , -SR10 , -NR12 R13 , -C(=O)R11 , -C(=O)OR2, NR12 R13 , -(C1-C12 )alkyl, -(C 1-C12 )heteroalkyl, -(C1-C12 )haloalkyl, -(C1-C12 )hydroxyalkyl, -(C1-C12 )aminoalkyl, -(C2- C12 )alkenyl, -(C2-C12 )alkynyl, -(C3-C9)cycloalkyl, -(C2-C7)heterocycloalkyl, aryl, or heteroaryl; n the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one, two, or three RZ; each RZ is independently halogen, -CN, -OR10 , -NR12 R13 , -NO2, -C(=O)R11 , -C(=O)OR10 , - C(=O)NR 12 R13 , -(C 1-C6)alkyl, -(C1-C6)haloalkyl, -(C1-C6)heteroalkyl, -(C1-C6)hydroxyalkyl, -(C1- C6)aminoalkyl, -(C2-C6)alkenyl, 6)alkynyl, -(C3-C7)cycloalkyl, or -(C2-C7)heterocycloalkyl; or two RZ on the same carbon are taken together to form an oxo; each R10 is independently H, -(C1-C6)alkyl, -(C1-C6)haloalkyl, -(C1-C6)heteroalkyl, -(C1- C6)hydroxyalkyl, -(C1-C6)aminoalkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C7)cycloalkyl, (C2- erocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally independently substituted with one, two, or three R10a ; each R10a is independently halogen, -CN, -ORa, -NRcRd, -C(=O)Rb, -C(=O)ORa, -C(=O)NRcRd, -(C1- yl, or -(C1-C6)haloalkyl; or two R10a on the same carbon are taken er to form an oxo; each R11 is independently 6)alkyl, -(C1-C6)haloalkyl, -(C1-C6)heteroalkyl, -(C1-C6)hydroxyalkyl, -(C 1-C6)aminoalkyl, -(C2-C6)alkenyl, 6)alkynyl, -(C3-C7)cycloalkyl, (C2- C7)heterocycloalkyl, aryl, or aryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally independently substituted with one, two, or three R11a ; 21305059_1 (GHMatters) P117933.NZ.1 each R11a is independently halogen, -CN, -ORa, , -C(=O)Rb, -C(=O)ORa, -C(=O)NRcRd, -(C1- C6)alkyl, or -(C1-C6)haloalkyl; or two R11a on the same carbon are taken together to form an oxo; each R12 and R13 is independently H, -(C1-C6)alkyl, -(C1-C6)haloalkyl, -(C1-C6)heteroalkyl, -(C1- C6)hydroxyalkyl, -(C1-C6)aminoalkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, 7)cycloalkyl, (C2- C7)heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally independently substituted with one, two, or three R12a ; or R12 and R13 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl ally substituted with one, two, or three R12b ; each R12a is independently halogen, -CN, -ORa, -NRcRd, -C(=O)Rb, -C(=O)ORa, -C(=O)NRcRd, -(C1- C6)alkyl, or -(C1-C6)haloalkyl; or two R12a on the same carbon are taken together to form an oxo; each R12b is independently halogen, -CN, -ORa, , -C(=O)Rb, -C(=O)ORa, -C(=O)NRcRd, -(C1- C6)alkyl, or -(C1-C6)haloalkyl; or two R12b on the same carbon are taken together to form an oxo; each Ra is independently H, 6)alkyl, -(C1-C6)haloalkyl, -(C1-C6)heteroalkyl, -(C1- C6)hydroxyalkyl, -(C1-C6)aminoalkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C7)cycloalkyl, (C2- C7)heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally independently substituted with one, two, or three halogen, -CN, -OH, -OMe, -NH2, -C(=O)Me, -C(=O)OH, -C(=O)OMe, -C(=O)NH2, or -(C1- C6)alkyl; each Rb is independently -(C1-C6)alkyl, -(C1-C6)haloalkyl, -(C1-C6)heteroalkyl, -(C1-C6)hydroxyalkyl, - (C 1-C6)aminoalkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C7)cycloalkyl, (C2-C7)heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally independently substituted with one, two, or three halogen, -CN, -OH, - OMe, -NH2, -C(=O)Me, -C(=O)OH, -C(=O)OMe, -C(=O)NH2, or -(C1-C6)alkyl; and each Rc and Rd is independently H, 6)alkyl, -(C1-C6)haloalkyl, -(C1-C6)heteroalkyl, -(C1- C6)hydroxyalkyl, -(C1-C6)aminoalkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C7)cycloalkyl, (C2- C7)heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, lkyl, heterocycloalkyl, aryl, and heteroaryl are optionally independently substituted with one, two, or three halogen, -CN, -OH, -OMe, -NH2, Me, -C(=O)OH, -C(=O)OMe, -C(=O)NH2, or -(C1- C6)alkyl; or Rc and Rd are taken together with the nitrogen atom to which they are attached to form a cycloalkyl optionally substituted with one, two, or three oxo, halogen, -CN, -OH, -OMe, - NH 2, Me, -C(=O)OH, -C(=O)OMe, -C(=O)NH2, or -(C1-C6)alkyl.
2. The compound of claim 1, or a pharmaceutically able salt or stereoisomer f, wherein R2 is H or -(C1-C6)alkyl. 21305059_1 ters) P117933.NZ.1
3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt or isomer thereof, wherein R2 is H.
4. The compound of any one of claims 1-3, or a ceutically acceptable salt or stereoisomer thereof, wherein R3 is H or -(C1-C6)alkyl.
5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or isomer thereof, wherein R3 is -(C1-C6)alkyl.
6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R3 is methyl.
7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R4 is H.
8. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R4 is methyl.
9. The compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer f; n the compound has the structure of Formula (Ia): Formula (Ia).
10. The compound of claim 1, or a pharmaceutically acceptable salt thereof; wherein the nd has the structure of Formula (Ib): 21305059_1 (GHMatters) P117933.NZ.1 Formula (Ib).
11. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1 is -(C1-C6)alkyl optionally substituted with one, two, or three R1a.
12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1 is -(C1-C6)alkyl tuted with one R1a.
13. The nd of any one of claims 1-12, or a pharmaceutically acceptable salt or stereoisomer f, wherein each R1a is independently halogen, -CN, -ORa, -NRcRd, -NRaC(=O)Rb, -NRaC(=O)NRcRd, =O)2Rb, or -NRaS(=O)2NRcRd.
14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R1a is independently -NRcRd or =O)2NRcRd.
15. The compound of any one of claims 1-14, or a ceutically acceptable salt or stereoisomer thereof, wherein each R1a is independently -NRcRd.
16. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R1a is independently -NRaS(=O)2NRcRd.
17. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt or stereoisomer f, wherein R1 is -CH2CH2NH2, -CH2CH2NHSO2NH2 or -CH2NHSO2NH2.
18. The compound of any one of claims 1-15 or 17, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1 is -CH2CH2NH2. 21305059_1 (GHMatters) P117933.NZ.1
19. The compound of any one of claims 1-14 or 16-17, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1 is -CH2CH 2NHSO 2NH 2.
20. The compound of any one of claims 1-14 or 16-17, or a pharmaceutically acceptable salt or stereoisomer f, wherein R1 is SO 2NH 2.
21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X is (C2-C7)heterocycloalkylene or heteroarylene; each optionally substituted with one, two, or three RX.
22. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X is (C2-C7)heterocycloalkylene optionally substituted with one, two, or three RX.
23. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X is heteroarylene optionally substituted with one, two, or three RX.
24. The compound of any one of claims 1-23, or a ceutically acceptable salt or stereoisomer thereof, wherein each RX is independently halogen, -ORa, -NRcRd, -(C1-C6)alkyl, or -(C1-C6)haloalkyl; or two RX on the same carbon are taken together to form an oxo.
25. The compound of any one of claims 1-24, or a pharmaceutically able salt or isomer thereof, wherein each RX is independently -NRcRd or -(C1-C6)alkyl; or two RX on the same carbon are taken together to form an oxo.
26. The compound of any one of claims 1-25, or a pharmaceutically acceptable salt or stereoisomer thereof, n Y is -(C2-C7)heterocycloalkylene or arylene; each optionally substituted with one, two, or three RY.
27. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Y is arylene optionally substituted with one, two, or three RY.
28. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each RY is independently n, -ORa, -NRcRd, -(C1-C6)alkyl, or 6)haloalkyl; or two RY on the same carbon are taken together to form an oxo.
29. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Z is halogen, -OR10 , -NR12 R13 , -(C1-C12 )alkyl, -(C1-C12 oalkyl, -(C1-C12 )haloalkyl, - 59_1 (GHMatters) P117933.NZ.1 (C 1-C12 )hydroxyalkyl, -(C1-C12 )aminoalkyl, -(C3-C9)cycloalkyl, or -(C2-C7)heterocycloalkyl; wherein the alkyl, cycloalkyl, and heterocycloalkyl are ally substituted with one, two, or three RZ.
30. The compound of any one of claims 1-29, or a ceutically able salt or stereoisomer thereof, wherein Z is -OR10 , -(C1-C12 , -(C1-C12 )haloalkyl, or 9)cycloalkyl; wherein the alkyl and cycloalkyl are optionally tuted with one, two, or three RZ.
31. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt or isomer thereof, wherein Z is -(C1-C12 )alkyl optionally substituted with one, two, or three RZ.
32. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Z is -(C1-C12 )haloalkyl optionally substituted with one, two, or three RZ.
33. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt or isomer thereof, wherein Z is -(C3-C9)cycloalkyl optionally substituted with one, two, or three RZ.
34. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt or stereoisomer thereof, n Z is -(C3-C7)cycloalkyl optionally substituted with one, two, or three RZ.
35. The compound of any one of claims 1-34, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each RZ is independently halogen, -OR10 , -NR12 R13 , or -(C1-C6)alkyl.
36. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt or isomer thereof, wherein each RZ is independently -(C1-C6)alkyl.
37. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Z is -OR10 .
38. The compound of any one of claims 1-30 or 37, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R10 is -(C1-C6)alkyl, -(C1-C6)haloalkyl, or 7)cycloalkyl.
39. The compound of claim 38, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R10 is -(C1-C6)alkyl or -(C3-C7)cycloalkyl.
40. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Z is -(C1-C12 )alkyl. 21305059_1 (GHMatters) P117933.NZ.1
41. The compound of any one of claims 1-30, or a pharmaceutically able salt or stereoisomer thereof, wherein Z is -(C1-C12)haloalkyl.
42. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Z is -(C3-C9)cycloalkyl.
43. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Z is -(C3-C7)cycloalkyl.
44. The compound of any one of claims 1-20, or a pharmaceutically able salt or stereoisomer f, wherein -X-Y-Z is , , , , , , , , , , , , , , , , , , , , , , , 21305059_1 (GHMatters) P117933.NZ.1 , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .
45. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt or stereoisomer f, wherein -X-Y-Z is , , , , , 21305059_1 (GHMatters) P117933.NZ.1 , , , , , , , , , , , , or .
46. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt or isomer thereof, wherein -X-Y-Z is , , , , , , , , or
47. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein -X-Y-Z is , , , or . 21305059_1 (GHMatters) P117933.NZ.1
48. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt or stereoisomer thereof, n -X-Y-Z is , , or .
49. A compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of: , , , , , , 21671120_1 (GHMatters) P117933.NZ.1 , , , , H2N NH2 HO OH N NH2 OH O HN H H N N O N N O O S NH2 O , , , , 21305059_1 ters) P117933.NZ.1 , , , , , , , , 59_1 (GHMatters) P117933.NZ.1 , , , , , , , , , , 21305059_1 ters) P117933.NZ.1 , , , , H2N NH2 F F HO OH N OH O HN H H NN N O N O NH2 O O O S NH2 , O , , , 21305059_1 ters) P117933.NZ.1 , , , , , , , , 21305059_1 ters) P117933.NZ.1 , , , , , , , , 59_1 (GHMatters) P117933.NZ.1 , , , , , , , , 21305059_1 ters) P117933.NZ.1 , , , , , , , , 59_1 (GHMatters) P117933.NZ.1 , , , and .
50. A pharmaceutical composition sing the compound of any one of claims 1-49, or a pharmaceutically acceptable salt or isomer thereof, and a pharmaceutically acceptable excipient.
51. Use of an effective amount of the compound of any one of claims 1-49, or a pharmaceutically acceptable salt or stereoisomer thereof, or the pharmaceutical composition of claim 50 comprising a compound of any one of claims 1-49, or a pharmaceutically acceptable salt or stereoisomer thereof, in the manufacture of a ment for treating a bacterial infection in a human.
52. The use of claim 51, wherein the nd, or a pharmaceutically acceptable salt thereof, is selected from the group consisting of: , , 21671120_1 (GHMatters) P117933.NZ.1 , , , , , , , , 59_1 (GHMatters) P117933.NZ.1 H2N NH2 HO OH N NH2 OH O HN H H N N O N N O O S NH2 O , , , , , , , , 59_1 (GHMatters) P117933.NZ.1 , , , , , , , , 21305059_1 ters) P117933.NZ.1 , , , , , and .
53. The use of claim 51 or 52, wherein the compound, or a pharmaceutically acceptable salt thereof, is ed from the group consisting of: , , 21305059_1 (GHMatters) P117933.NZ.1 , , , , , , H2N NH2 HO OH N NH2 OH O HN H H N N O N N O O S NH2 , O , 59_1 (GHMatters) P117933.NZ.1 , , , , , , , , 59_1 (GHMatters) P117933.NZ.1 , , , , , , , , , , 59_1 (GHMatters) P117933.NZ.1 and .
54. The use of any one of claims 51-53, wherein the nd, or a pharmaceutically acceptable salt thereof, is selected from the group consisting of: , , , , , , 21305059_1 (GHMatters) P117933.NZ.1 , , H2N NH2 F F HO OH N OH O HN H H NN N O N O NH2 O O O S NH2 O , , , , , , and 59_1 (GHMatters) P117933.NZ.1
55. The use of any one of claims 51-54, wherein the nd, or a pharmaceutically acceptable salt thereof, is selected from the group consisting of: , , , , , , 21305059_1 (GHMatters) P117933.NZ.1 , and .
56. The use of claim 51, n the compound, or a pharmaceutically acceptable salt thereof, is (8S,11S,14S)hydroxymethyl[methyl-[(2S)[[4-amino(4-tert-butylphenyl)methylpyrimidinecarbonyl ]amino](sulfamoylamino)propanoyl]amino]-10,13-dioxo-3,17-bis[(2R)amino- 2-hydroxy-propoxy]-9,12-diazatricyclo[13.3.1.12,6]icosa-1(18),2(20),3,5,15(19),16-hexaenecarboxylic acid.
57. The use of claim 51, wherein the compound, or a pharmaceutically acceptable salt thereof, is (8S,11S,14S)hydroxymethyl[methyl-[(2S)[[4-methyl[4-(1- methylcyclopropyl)phenyl]pyrimidinecarbonyl]amino](sulfamoylamino)propanoyl]amino]-10,13- dioxo-3,17-bis[(2R)aminohydroxy-propoxy]-9,12-diazatricyclo[13.3.1.12,6]icosa- 1(18),2(20),3,5,15(19),16-hexaenecarboxylic acid.
58. The use of claim 51, wherein the compound, or a pharmaceutically acceptable salt thereof, is (8S,11S,14S)hydroxymethyl[methyl-[(2S)amino[[4-amino(4-tert-butylphenyl) methyl-pyrimidinecarbonyl]amino]butanoyl]amino]-10,13-dioxo-3,17-bis[(2R)aminohydroxypropoxy ]-9,12-diazatricyclo[13.3.1.12,6]icosa-1(18),2(20),3,5,15(19),16-hexaenecarboxylic acid.
59. The use of claim 51, wherein the compound, or a ceutically able salt thereof, is (8S,11S,14S)hydroxymethyl[methyl-[(2S)amino[[4-methyl[4-(1- methylcyclopropyl)phenyl]pyrimidinecarbonyl]amino]butanoyl]amino]-10,13-dioxo-3,17-bis[(2R) aminohydroxy-propoxy]-9,12-diazatricyclo[13.3.1.12,6]icosa-1(18),2(20),3,5,15(19),16-hexaene carboxylic acid.
60. The use of claim 51, wherein the compound, or a pharmaceutically acceptable salt f, is (8S,11S,14S)hydroxymethyl[methyl-[(2S)amino[[2-(4-tert-butylphenyl)amino difluoromethyl-pyrimidinecarbonyl]amino]butanoyl]amino]-10,13-dioxo-3,17-bis[(2R)amino hydroxy-propoxy]-9,12-diazatricyclo[13.3.1.12,6]icosa-1(18),2(20),3,5,15(19),16-hexaenecarboxylic acid. 21305059_1 (GHMatters) P117933.NZ.1
61. The use of claim 51, wherein the nd, or a pharmaceutically acceptable salt f, is (8S,11S,14S)[[(2S)[[4-amino(4-tert-butylphenyl)(difluoromethyl)pyrimidine carbonyl]amino](sulfamoylamino)propanoyl]-methyl-amino]-3,17-bis[(2R)aminohydroxypropoxy ]hydroxymethyl-10,13-dioxo-9,12-diazatricyclo[13.3.1.12,6]icosa- 1(18),2(20),3,5,15(19),16-hexaenecarboxylic acid.
62. The use of any one of claims 51-61, wherein the bacterial infection is a lepB-mediated bacterial infection.
63. The use of claim 62, wherein the bacterial infection is an infection involving Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenotrophomonas maltophilia, Burkholderia a, Aeromonas hydrophilia, Escherichia coli, Citrobacter freundii, ella typhimurium, Salmonella typhi, ella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter nes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Francisella tularensis, Morganella morganii, Proteus mirabilis, s vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Bordetella pertussis, Bordetella parapertussis, Bordetella iseptica, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, hilus parahaemolyticus, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Branhamella catarrhalis, Helicobacter pylori, Campylobacter fetus, obacter jejuni, Campylobacter coli, Borrelia burgdorferi, Vibrio ae, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, ria gonorrhoeae, Neisseria itidis, Kingella, Moraxella, Gardnerella vaginalis, Bacteroides is, Bacteroides distasonis, Bacteroides 3452A homology group, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, Bacteroides splanchnicus, Clostridium difficile, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium leprae, Corynebacterium eriae, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus es, coccus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, lococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, or Staphylococcus saccharolyticus.
64. The use of any one of claims 51-63, wherein the bacterial infection is an infection involving Acinetobacter baumannii, ella pneumoniae or Pseudomonas aeruginosa. 21305059_1 (GHMatters) P117933.NZ.1
65. The use of any one of claims 51-64, wherein the bacterial infection is an ion involving obacter baumannii.
66. The use of any one of claims 51-63, wherein the bacterial infection is an infection ing Burkholderia cepacia.
67. The use of any one of claims 51-62, wherein the bacterial ion is an ion involving a Gram-negative bacteria.
68. The use of any one of claims 51-67, wherein the medicament is to be administered in ation with a second therapeutic agent.
69. The use of claim 68, wherein the second therapeutic agent is not a SpsB or LepB inhibitor.
70. The use of claim 68 or 69, wherein the second therapeutic agent is an aminoglycoside antibiotic, fluoroquinolone antibiotic, ß-lactam antibiotic, macrolide antibiotic, glycopeptide antibiotic, rifampicin, chloramphenicol, fluoramphenicol, colistin, mupirocin, acin, daptomycin, or linezolid.
71. The use of claim 70, wherein the second therapeutic agent is a ß-lactam antibiotic.
72. The use of claim 71, wherein the ß-lactam antibiotic is selected from penicillins, monobactams, cephalosporins, cephamycins, and carbapenems.
73. The use of claim 72, n the ß-lactam antibiotic is selected from Azlocillin, Amoxicillin, Ampicillin, Doripenem, Meropenem, Biapenem, Cefamandole, Imipenem, Mezlocillin, Cefmetazole, Cefprozil, cillin/tazobactam, Carbenicillin, Cefaclor, Cephalothin, Ertapenem, Cefazolin, Cefepime, Cefonicid, Cefoxitin, Ceftazidime, Oxacillin, Cefdinir, Cefixime, Cefotaxime, tan, Cefpodoxime, Ceftizoxime, Ceftriaxone, Faropenem, Mecillinam, Methicillin, Moxalactam, Ticarcillin, Tomopenem, Ceftobiprole, Ceftaroline, Flomoxef, Cefiprome, and Cefozopran.
74. The use of any one of claims 51-73, wherein the medicament is to be administered in ation with a ß-lactamase inhibitor. 21671120_1 (GHMatters) P117933.NZ.1
NZ790559A 2020-05-27 Macrocyclic broad spectrum antibiotics NZ790559B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962853457P 2019-05-28 2019-05-28
NZ783605A NZ783605A (en) 2019-05-28 2020-05-27 Macrocyclic broad spectrum antibiotics

Publications (2)

Publication Number Publication Date
NZ790559A true NZ790559A (en) 2025-05-02
NZ790559B2 NZ790559B2 (en) 2025-08-05

Family

ID=

Also Published As

Publication number Publication date
KR102450071B1 (en) 2022-09-30
CL2021003153A1 (en) 2022-07-29
KR20220003629A (en) 2022-01-10
KR102764861B1 (en) 2025-02-06
CN115215923A (en) 2022-10-21
JP2022137011A (en) 2022-09-21
LT3968983T (en) 2023-10-10
TW202404953A (en) 2024-02-01
JP7078807B2 (en) 2022-05-31
EP4289480A2 (en) 2023-12-13
DK3968983T3 (en) 2023-10-30
TWI919116B (en) 2026-03-21
JP2024147560A (en) 2024-10-16
TWI815017B (en) 2023-09-11
JP7842812B2 (en) 2026-04-08
SA521430976B1 (en) 2023-12-11
SG11202112920SA (en) 2021-12-30
CR20210682A (en) 2022-06-02
CN115215923B (en) 2026-05-19
MX2021014554A (en) 2022-03-17
EP4289480A3 (en) 2024-02-21
IL295889A (en) 2022-10-01
JP7508507B2 (en) 2024-07-01
IL288294B (en) 2022-09-01
EP3968983B1 (en) 2023-09-13
PE20230383A1 (en) 2023-03-06
CA3141853A1 (en) 2020-12-03
SI3968983T1 (en) 2023-11-30
IL295889B1 (en) 2024-09-01
KR102450071B9 (en) 2026-04-17
JP2022525693A (en) 2022-05-18
RS64852B1 (en) 2023-12-29
KR102688389B1 (en) 2024-07-24
HRP20231497T8 (en) 2024-08-02
AU2023200369A1 (en) 2023-02-23
NZ783605A (en) 2022-08-26
AU2023200369B2 (en) 2024-10-24
AU2020282975B2 (en) 2023-02-02
WO2020243155A1 (en) 2020-12-03
ZA202502195B (en) 2025-10-29
BR112021024010A2 (en) 2022-05-17
FI3968983T3 (en) 2023-11-01
EP3968983A1 (en) 2022-03-23
CN114007605B (en) 2022-07-15
US20200377463A1 (en) 2020-12-03
EP3968983A4 (en) 2022-06-22
IL295889B2 (en) 2025-01-01
ES2961566T3 (en) 2024-03-12
TW202110812A (en) 2021-03-16
US11208387B2 (en) 2021-12-28
AR119019A1 (en) 2021-11-17
MA55981B1 (en) 2024-02-29
PT3968983T (en) 2023-10-04
KR20240101729A (en) 2024-07-02
KR20250020719A (en) 2025-02-11
CO2021017561A2 (en) 2022-01-17
HRP20231497T1 (en) 2024-03-01
PH12021552972A1 (en) 2022-07-25
KR102764861B9 (en) 2026-04-16
HUE063847T2 (en) 2024-02-28
US20220135528A1 (en) 2022-05-05
IL288294A (en) 2022-01-01
MA55981A (en) 2022-03-23
KR102688389B9 (en) 2026-04-08
KR20220137165A (en) 2022-10-11
PE20240066A1 (en) 2024-01-11
AU2020282975A1 (en) 2022-01-20
PL3968983T3 (en) 2024-03-18
CN114007605A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
JP2022137011A5 (en)
RU2016146581A (en) MACROCYCLIC ANTIBIOTICS OF A WIDE SPECTRUM OF ACTION
RU2013104951A (en) CYCLIC BORONIC ACID-ETHERIC DERIVATIVES AND THEIR USE IN THERAPY
JP2019527196A5 (en)
JP2021522167A5 (en)
JP2023159197A5 (en)
JP2016501864A5 (en)
JP2017517567A5 (en)
JP2020507564A5 (en)
CA2504448A1 (en) Transcription factor modulating compounds and methods of use thereof
RU2018122505A (en) MACROCYCLIC ANTIBIOTICS OF A WIDE SPECTRUM OF ACTION
US11007206B2 (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
RU2016107436A (en) LINEAR PEPTIDE ANTIBIOTICS
FI3986419T3 (en) Boronic acid derivatives and therapeutic uses thereof
JP2016528257A5 (en)
US9687497B1 (en) Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
SI2344129T1 (en) Aerosol fluoroquinolone formulations for improved pharmacokinetics
JP2023518418A5 (en)
US9241947B2 (en) Boronic acid derivatives and therapeutic uses thereof
NEU Cephalosporin antibiotics as applied in surgery of bones and joints
CN107530364A (en) Methods of Treating Bacterial Infections
RU2018122498A (en) MACROCYCLIC ANTIBIOTICS OF A WIDE SPECTRUM OF ACTION
WO2011101710A1 (en) Efflux pump inhibitors
JP2019502659A5 (en)
NZ783605A (en) Macrocyclic broad spectrum antibiotics

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE INVENTOR HAS BEEN CORRECTED TO 3734168, STURINO, CLAUDIO, C/O PARAZA PHARMA, INC.2525 MARIE-CURIE AVENUEMONTREAL, QUEBEC H4S 2E1, , CA; 3811842, KOEHLER, MICHAEL FRIEDRICH THOMAS, C/O GENENTECH, INC.1 DNA WAYSOUTH SAN FRANCISCO, CALIFORNIA 94080, , US; 3811843, SMITH, PETER ANDREW, C/O GENENTECH, INC.1 DNA WAYSOUTH SAN FRANCISCO, CALIFORNIA 94080, , US; 3811844, WINTER, DANA, C/O PARAZA PHARMA, INC.2525 MARIE-CURIE AVENUEMONTREAL, QUEBEC H4S 2E1, , CA; 3811845, SOW, BOUBACAR, C/O PARAZA PHARMA, INC.2525 MARIE-CURIE AVENUEMONTREAL, QUEBEC H4S 2E1, , CA; 3811846, PELLETIER, GUILLAUME, 2030 RUE SAINTE-MARIESAINT-LAZARE, QUEBEC J7T 2V4, , CA; 3811847, BOUDREAULT, JONATHAN, 227 RUE DU BOISEL'

Effective date: 20241011

PSEA Patent sealed